Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

10x Genomics (TXG) Leases (2020 - 2026)

10x Genomics' Leases history spans 6 years, with the latest figure at $60.4 million for Q4 2025.

  • On a quarterly basis, Leases rose 5.52% to $60.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $60.4 million, a 5.52% increase, with the full-year FY2025 number at $60.4 million, up 5.52% from a year prior.
  • Leases hit $60.4 million in Q4 2025 for 10x Genomics, down from $63.6 million in the prior quarter.
  • Over the last five years, Leases for TXG hit a ceiling of $75.7 million in Q1 2022 and a floor of $54.1 million in Q2 2021.
  • Historically, Leases has averaged $64.3 million across 5 years, with a median of $62.8 million in 2024.
  • Biggest five-year swings in Leases: soared 35.66% in 2022 and later fell 15.91% in 2024.
  • Tracing TXG's Leases over 5 years: stood at $60.9 million in 2021, then rose by 14.71% to $69.9 million in 2022, then decreased by 6.47% to $65.4 million in 2023, then fell by 12.35% to $57.3 million in 2024, then increased by 5.52% to $60.4 million in 2025.
  • Business Quant data shows Leases for TXG at $60.4 million in Q4 2025, $63.6 million in Q3 2025, and $62.7 million in Q2 2025.